Xiaozheng Kang

Research interest in Surgical Oncology, Clinical Oncology, Translational Medicine, and Personalized Medicine.

The Associate Editor for social media, the Diseases of the Esophagus (DOTE) Journal.

• Kang X, Qin J, Zhang R, et al. 2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer. Ann Esophagus. 2021;4:33. doi: 10.21037/aoe-21-64.
• Kang X, Zhang C, Zhou H, et al. Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers. Ann Thorac Surg. 2020;109(3):856-863. doi:10.1016/j.athoracsur.2019.09.088.
• Qiu B, Kang X, Chen KN, et al. Clinical outcomes following an initial experience with a novel powered vascular stapler in video-assisted thoracoscopic lobectomies: results of a Chinese multi-center study. J Thorac Dis. 2019;11(5):1973-1979. doi:10.21037/jtd.2019.04.89.
• Zhou H, Kang X, Dai L, et al. Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer. Thorac Cancer. 2018;9(8):1062-1068. doi:10.1111/1759-7714.12790.
• Xu T, Kang X, You X, et al. Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma. Theranostics. 2017;7(6):1437-1446. Published 2017 Apr 2. doi:10.7150/thno.16558.
• Kang X, Liu H, Onaitis MW, et al. Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis. 2016;37(3):280-289. doi:10.1093/carcin/bgw014.